Immunology Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Evaluation of ALLERgen Specific Vaccination of DOG Allergic Patients in Swedish Practice

This Phase 4 trial is testing a new allergy vaccine for adults with moderate to severe dog allergy and asthma. Conducted by Karolinska Institutet in Sweden, the study aims to see if the vaccine can reduce allergic symptoms and improve breathing over one year. If successful, it could provide a new treatment option to help people who suffer from dog allergies and related asthma manage their condition better.

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Novartis Pharmaceuticals conducted this Phase 2 trial in the United States, testing remibrutinib, an oral medication for adults with peanut allergy. The study included 76 participants and results are now available. This treatment could offer a new way to increase tolerance to peanuts and lower the risk of severe allergic reactions, helping people with peanut allergies live more safely.

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

This upcoming Phase 3 trial by Octapharma will test Panzyga, an intravenous immunoglobulin, to prevent serious infections in patients with low antibody levels who are receiving autoimmune or rheumatic treatments. The study plans to enroll 360 participants but has not started recruiting yet. If successful, it could reduce infection risks for people undergoing treatments that weaken their immune systems, improving safety during therapy.

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies

Conducted by the Masonic Cancer Center at the University of Minnesota, this study is exploring the use of stem cell transplants for patients with rare primary immune deficiencies. This treatment could offer a new option for people with serious immune disorders who currently have limited choices. The trial is active but not recruiting and takes place at a single site in the United States.

Allergenic Risk Assessment of Hemp Seed

This study by University Hospital, Angers, investigates the allergy risks of hemp seed consumption for people allergic to cannabis, tree nuts, or seeds. By enrolling 35 participants and using blood and skin tests, the trial aims to better understand potential allergic reactions. The results could help patients avoid severe allergies and improve food safety for those with related allergies.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.